EBR Systems, Inc. announced the first commercial implants of WiSE Technology, the world's only wireless endocardial pacing system for cardiac resynchronization therapy (CRT). CRT is a proven therapy that reduces mortality and improves clinical outcomes in people suffering from heart failure. The implants were performed in James Cook University Hospital, UK and Na Homolce Hospital, Czech Republic.

WiSE Technology is an implantable pacing system capable of delivering energy to the heart without using a pacing lead (or wire) to conduct the energy. It was designed to address the persistent limitations of current CRT systems; where approximately 30-40% of patients who receive a conventional CRT device fail to respond to therapy or suffer lead-related failures. Preliminary results from the SELECT-LV study, where patients were implanted with WiSE Technology, demonstrated improvement in 81% of patients who had previously failed conventional CRT treatment.